Creative Medical Technology Holdings, Inc. (CELZ) stock
CELZNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.53−0.09 (-14.35%)
Close on Nov 13, 2026Market cap $3.48MP/E –Yield –
Creative Medical Technology r&d expenses
Research and development expenses are spending on new products and technology.
Creative Medical Technology's R&D Expenses for the twelve months ending Sep 30, 2026 was $3.15M, up 44.5% year over year. For fiscal 2025 it was $2.26M, down 5.9% from the year before. The highest annual figure on record is $6.27M in fiscal 2022.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.26M | -5.9% |
| FY2024 | Dec 31, 2024 | $2.40M | +21.8% |
| FY2023 | Dec 31, 2023 | $1.97M | -68.6% |
| FY2022 | Dec 31, 2022 | $6.27M | +5641.8% |
| FY2021 | Dec 31, 2021 | $109.18K | – |
| FY2020 | Dec 31, 2020 | $0 | – |
| FY2019 | Dec 31, 2019 | $0 | -100.0% |
| FY2018 | Dec 31, 2018 | $96.62K | -62.9% |
| FY2017 | Dec 31, 2017 | $260.09K | +204.8% |
| FY2016 | Dec 31, 2016 | $85.33K | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $1.60M | +244.3% |
| Q2 FY2026 | Jun 30, 2026 | $459.20K | -8.4% |
| Q1 FY2026 | Mar 31, 2026 | $541.66K | -27.1% |
| Q4 FY2025 | Dec 31, 2025 | $550.08K | +16.6% |
| Q3 FY2025 | Sep 30, 2025 | $465.15K | -20.0% |
| Q2 FY2025 | Jun 30, 2025 | $501.26K | -45.8% |
| Q1 FY2025 | Mar 31, 2025 | $743.30K | +76.0% |
| Q4 FY2024 | Dec 31, 2024 | $471.84K | +35.0% |
| Q3 FY2024 | Sep 30, 2024 | $581.80K | -41.4% |
| Q2 FY2024 | Jun 30, 2024 | $924.75K | +198.8% |
| Q1 FY2024 | Mar 31, 2024 | $422.39K | +32.4% |
| Q4 FY2023 | Dec 31, 2023 | $349.41K | -93.5% |
| Q3 FY2023 | Sep 30, 2023 | $992.72K | +329.9% |
| Q2 FY2023 | Jun 30, 2023 | $309.48K | -53.1% |
| Q1 FY2023 | Mar 31, 2023 | $319.03K | +3090.3% |
| Q4 FY2022 | Dec 31, 2022 | $5.37M | +10636.4% |
| Q3 FY2022 | Sep 30, 2022 | $230.94K | +290.2% |
| Q2 FY2022 | Jun 30, 2022 | $659.70K | – |
| Q1 FY2022 | Mar 31, 2022 | $10.00K | – |
| Q4 FY2021 | Dec 31, 2021 | $50.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $59.18K | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $0 | – |
| Q4 FY2020 | Dec 31, 2020 | $0 | – |
| Q3 FY2020 | Sep 30, 2020 | $0 | – |
| Q4 FY2019 | Dec 31, 2019 | $0 | -100.0% |
| Q3 FY2019 | Sep 30, 2019 | $0 | -100.0% |
| Q2 FY2019 | Jun 30, 2019 | $0 | -100.0% |
| Q1 FY2019 | Mar 31, 2019 | $0 | -100.0% |
| Q4 FY2018 | Dec 31, 2018 | $86.34K | -1.1% |
| Q3 FY2018 | Sep 30, 2018 | $2.88K | -96.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.20K | -83.3% |
| Q1 FY2018 | Mar 31, 2018 | $3.20K | -94.7% |
| Q4 FY2017 | Dec 31, 2017 | $87.34K | +391.5% |
| Q3 FY2017 | Sep 30, 2017 | $87.73K | – |
| Q2 FY2017 | Jun 30, 2017 | $25.19K | – |
| Q1 FY2017 | Mar 31, 2017 | $59.83K | – |
| Q4 FY2016 | Dec 31, 2016 | $17.77K | – |
See a number that looks wrong?